CAMBRIDGE, MA and ROCKVILLE, MD, USA I
April 28, 2025 I
Clasp Therapeutics, a biotechnology company bringing unparalleled precision to immuno-oncology with next-generation T-cell engagers (TCEs), today announced
new data
supporting the development of its lead program, CLSP-1025. Nonclinical data underpinning the GUARDIAN-101 Phase 1 study of CLSP-1025 were presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago, IL on April 27, 2025.
Clasp’s approach centers on developing precision TCEs with absolute tumor specificity by targeting oncogenic driver mutations presented by human leukocyte antigen (HLA) on cancer cells. CLSP-1025 exemplifies this strategy, selectively engaging the p53 R175H mutant peptide, presented by HLA-A*02:01, to direct a potent T cell response. Given that p53 is frequently mutated in cancer—with R175H as its most common variant—and HLA-A*02:01 is highly prevalent in the US, Europe, and Asia, CLSP-1025 has broad clinical potential.
The promising nonclinical data presented at AACR support the clinical development of CLSP-1025 as a potentially transformative therapy designed to deliver durable anti-tumor responses while minimizing impact on healthy tissue. As the first clinical-stage TCE to target an oncogenic driver mutation, CLSP-1025 is currently being evaluated in the GUARDIAN-101 Phase 1 clinical trial. This study is assessing the safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of CLSP-1025 in HLA-A*02:01–positive patients with advanced solid tumors harboring the p53 R175H mutation.
“At Clasp, we’re pioneering a new era of precision immuno-oncology – one that goes straight to the source by targeting the mutations that drive cancer formation and progression,” said Vipin Suri, Ph.D., Chief Scientific Officer of Clasp Therapeutics. “The nonclinical data we presented reinforce the promise of our approach and the potential of CLSP-1025 in the GUARDIAN-101 Phase 1 trial. These data mark a meaningful step forward in our mission to deliver targeted, more effective therapies for patients with limited options.”
Data Highlights:
About GUARDIAN-101 and CLSP-1025
Clasp’s Phase 1 GUARDIAN-101 dose escalation study evaluates the safety and initial anti-tumor activity of CLSP-1025. CLSP-1025 is a bispecific antibody-like molecule that directs a patient’s T cells to the tumor, generating a precise immune response to selectively and potently eliminate cancer cells. CLSP-1025 is designed to target the p53 R175H peptide in the context of HLA-A*02:01. Enrolled patients must be HLA-A*02:01 positive and have an advanced solid tumor that harbors the p53 R175H mutation. This Phase 1 study will identify the dose of CLSP-1025 for use in future studies. Visit
clinicaltrials.gov
(NCT06778863) for more details.
About Clasp Therapeutics, Inc.
Clasp is pioneering precision in immuno-oncology through next-generation T-cell engagers (TCEs) that target tumor-specific oncogenic driver mutations common across hard-to-treat cancers. Clasp’s platform identifies mutation-associated neoantigens and develops TCEs that can selectively bind HLA (human leukocyte antigen)-presented peptides derived from these oncogenic drivers. With their unique properties, Clasp’s TCEs are adaptable for application across a variety of cancers with high unmet need. Please visit
www.clasptx.com
to learn more.
SOURCE:
Clasp Therapeutics